IQVIA™ Real-World Insights Bibliography

Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data.
Author(s): Husereau D1, Goodfield J2, Leigh R3, Borrelli R2, Cloutier M2, Gendron A4,5.
Affiliations(s): 1Department of Epidemiology and Community Medicine, School of Epidemiology and Public Health, University of Ottawa, Room 101, 600 Peter Morand Crescent, Ottawa, ON K1G 5Z3 Canada 2IQVIA, Mississauga, ON Canada 3Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB Canada 4AstraZeneca Canada Inc, Mississauga, ON Canada 5Department of Medicine, University of Montreal, Montreal, QC Canada
Publication(s):  Allergy Asthma Clin Immunol. 2018 Apr 24;14:15.
Document Type(s): Article,
Countries: Canada,
C:
Y:

2018
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Clinical characteristics of Glioblastoma Multiforme (GBM) Patients Who Reached 400 Days Post Diagnostic from a Retrospective Real-World Data
Author(s):  Mitrofan L.M.1,Krukas-Hampel M.R.2, Mendoza L.A.3
Affiliations(s): 1 IQVIA, Paris, FR; 2IQVIA New York, US; 3IQVIA, Prague, CZ
Publication(s):  ESMO 2018
Document Type(s): Poster,
Countries: Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK,
C:
Y:
Oncology,
2018
  L:
A:
English
  Add to report
 
 
Clinical Characteristics of 3,030 Glioblastoma Multiforme (GBM) Patients in High, Upper Middle and Lower Middle Economic Regions Based on Real-World Data (RWD)
Author(s):  Mitrofan L1 , M.R. Krukas-Hampel M.R2 , L.A. Mendoza L.A3
Affiliations(s): IQVIA, Paris, FR; IQVIA New York, US; IQVIA, Prague, CZ
Publication(s):  ESMO 2018
Document Type(s): Poster,
Countries: Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK,
C:
Y:
Oncology,
2018
  L:
A:
English
  Add to report
 
 
Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study
Author(s): John K. Marshall MD, MSc, FRCPC 1, Louis Bessette MD, MSc, FRCPC 2, Carter Thorne MD, FRCPC 3, Neil H. Shear MD, FRCPC 4, 5, Gerald Lebovic PhD 6, 7, Sebastien K. Gerega MBA 8, Brad Millson MBS 8, Driss Oraichi PhD 8, Tania Gaetano B.Comm, MIS 9, Sandra Gazel MBA, MSc 9, Martin G. Latour PhD 9, Marie-Claude Laliberté PhD 9
Affiliations(s): 1 Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada 2 Department of Medicine, Laval University, Quebec City, Quebec, Canada 3 Southlake Regional Health Centre, Newmarket, Ontario, Canada 4 Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada 5 Department of Medicine, Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada 6 Applied Health Research Centre, St. Michael's Hospital, Toronto, Ontario, Canada 7 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada 8 QuintilesIMS, Kirkland, Quebec, Canada 9 AbbVie Corporation, St. Laurent, Quebec, Canada
Publication(s):  Clinical Therapeutics, Volume 40, Issue 3 pages 415-429.e6
Document Type(s): 
Countries: Canada,
Click here for the abstract
C:
Y:
Miscellaneous,
2018
  L:
A:
English
Observational study, Retrospective cohort analysis,
  Add to report
 
 
Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study
Author(s): Louis BessetteEmail author, Gerald Lebovic, Brad Millson, Katia Charland, Krishna Donepudi, Tania Gaetano, Valencia Remple, Martin G. Latour, Sandra Gazel, Marie-Claude Laliberté, Carter Thorne
Affiliations(s): 1. Department of Medicine, Laval University, Quebec, Canada 2. Applied Health Research Centre, St. Michael’s Hospital, Toronto, Canada 3. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada 4. QuintilesIMS, Quebec, Canada 5. AbbVie Corporation, Quebec, Canada 6. Southlake Regional Health Centre, Newmarket, Canada
Publication(s):  Rheumatology and Therapy, June 2018, Volume 5, Issue 1, pages 75-85
Document Type(s): 
Countries: Canada,
Click here for the abstract
C:
Y:
Miscellaneous,
2018
  L:
A:
English
Longitudinal study,
  Add to report
 
 
Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study
Author(s):  John K. Marshall MD, MSc, FRCPC 1, Louis Bessette MD, MSc, FRCPC 2, Neil H. Shear MD, FRCPC 3, 4, Gerald Lebovic PhD 5, 6, Jennifer Glass PhD 7, Brad Millson MBS 7, Tania Gaetano BComm, MIS 8, Sandra Gazel MBA, MSc 8, Martin G. Latour PhD 8, Marie-Claude Laliberté PhD 8, J. Carter Thorne MD, FRCP 5, 6
Affiliations(s): 1 Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada 2 Department of Medicine, Laval University, Quebec City, Quebec, Canada 3 Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada 4 Department of Medicine, Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada 5 Applied Health Research Centre, St. Michael's Hospital, Toronto, Ontario, Canada 6 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada 7 QuintilesIMS, Health Access and Outcomes, Kirkland, Quebec, Canada 8 AbbVie Corporation, St. Laurent, Quebec, Canada
Publication(s): 
Document Type(s): 
Countries: Canada,
Click here for the abstract
C:
Y:
Miscellaneous,
2018
  L:
A:
English
Longitudinal study, Retrospective cohort analysis,
  Add to report
 
 
Assessing the Benefits of Co-pay Card Usage Among Diabetic Patients in Canada
Author(s): Jing Guo 1, Christian Silva 1, Chris Stewart 1, Andrew Leung 1, Behlool Khan 2, Johanna Mancini 2
Affiliations(s): 1 Department of Mechanical and Industrial Engineering, University of Toronto 2 IQVIA
Publication(s): 
Document Type(s): Poster,
Countries: Canada,
Click here for the abstract
C:
Y:
Diabetes,
2018
  L:
A:
English
Retrospective cohort analysis,
  Add to report
 
 
Cost-Effectiveness Analysis of Brodalumab in Moderate-to-Severe Plaque Psoriasis in Canada
Author(s): Xue, W. 1, Gray, E. 1, Khoudigian-Sinani, S. 2, Barbeau, M. 3, Frieder, D. 3
Affiliations(s): 1 IQVIA, London, UK, 2 IQVIA Mississauga, ON, Canada, 3 Valeant Canada LP, Laval QC, Canada
Publication(s):  ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD, USA
Document Type(s): Poster,
Countries: Canada,
Click here for the abstract
C:
Y:
Dermatology,
2018
  L:
A:
English
Database Study,
  Add to report
 
 
Efficacy of Brodalumab in the Treatment of Moderate-to-Severe Psoriasis: A Network Meta-Analysis
Author(s): Xue, W. 1, Saharia, P. 2, Gray, E. 1, Khoudigian-Sinani, S. 3, Barbeau, M. 4, Frieder, D. 4
Affiliations(s): 1. IQVIA, London, UK, 2. IQVIA Gurugram, India, 3. IQVIA Mississauga, ON, Canada, 4. Valeant Canada LP, Laval QC, Canada
Publication(s): 
Document Type(s): Poster,
Countries: Canada,
Click here for the abstract
C:
Y:
Dermatology,
2018
  L:
A:
English
Meta analysis,
  Add to report
 
 
pCPA CHANGES AND IMPACT TO MARKET ACCESS IN CANADA: RESULTS FROM AN OBSERVATIONAL CROSS-SECTIONAL STUDY
Author(s): Minhas, Jagdeep, M.Biotech 1; Iqbal-Khan, Sarah, MBA 2; Laforty, Callahan, MSc 2; Millson, Brad, MBS 1
Affiliations(s): 1 1 Health Access and Outcomes, IQVIA, 535 Legget Drive, Kanata, ON, K2K 3B8 2 Health Access and Outcomes, IQVIA, 6755 Century Avenue, Mississauga, ON, L5N 6A4
Publication(s):  2018 CADTH Symposium, April 15-17, 2018, Halifax, NS, Canada
Document Type(s): Poster,
Countries: Canada,
Click here for the abstract
C:
Y:
Miscellaneous,
2018
  L:
A:
English
Observational study,
  Add to report
 
 
 1 of 10 Next Page Last Page